Protalix BioTherapeutics Inc (FRA:PBDA)
€ 1.0305 0.022 (2.18%) Market Cap: 87.92 Mil Enterprise Value: 70.56 Mil PE Ratio: 0 PB Ratio: 3.28 GF Score: 42/100

Q3 2020 Protalix Biotherapeutics Inc Earnings Call Transcript

Oct 30, 2020 / 12:30PM GMT
Release Date Price: €2.76
Operator

Greetings and welcome to the Protalix Biopharmaceuticals Third Quarter 2020 Financial Results and Business update. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Investor Relations, Chuck Padala. Thank you, Chuck, you may begin.

Charles Padala;LifeSci Advisors;Managing Director
LLC;Investor Relations,

Thank you, Paul. Welcome to the Protalix BioTherapeutics Third Quarter 2020 Financial Results and Business Update Conference call. With me today are Dror Bashan, Protalix's President and CEO, as well as Eyal Rubin, Protalix's CFO. A press release announcing the results and the update was issued yesterday morning and is now available on the Protalix' website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and the teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot